Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

MLA

Paton, Nicholas I., et al. Efficacy and Safety of Dolutegravir or Darunavir in Combination with Lamivudine plus Either Zidovudine or Tenofovir for Second-Line Treatment of HIV Infection (NADIA): Week 96 Results from a Prospective, Multicentre, Open-Label, Factorial, Randomised, Non-Inferiority Trial. May 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.core.ac.uk....6933a9139dd2f1250f9b6c8d7ffaf973&authtype=sso&custid=ns315887.

APA

Paton, N. I., Musaazi, J., Kityo, C., Walimbwa, S., Hoppe, A., Balyegisawa, A., Asienzo, J., Kaimal, A., Mirembe, G., Lugemwa, A., Ategeka, G., Borok, M., Mugerwa, H., Siika, A., Odongpiny, E. L. A., Castelnuovo, B., Kiragga, A., Kambugu, A., & NADIA Trial Team. (2022). Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.

Chicago

Paton, Nicholas I, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe, Apolo Balyegisawa, Jesca Asienzo, et al. 2022. “Efficacy and Safety of Dolutegravir or Darunavir in Combination with Lamivudine plus Either Zidovudine or Tenofovir for Second-Line Treatment of HIV Infection (NADIA): Week 96 Results from a Prospective, Multicentre, Open-Label, Factorial, Randomised, Non-Inferiority Trial,” May. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.core.ac.uk....6933a9139dd2f1250f9b6c8d7ffaf973&authtype=sso&custid=ns315887.